Publications

Low Bacterial Biomass in Human Pancreatic Cancer and Adjacent Normal Tissue

May MS, Park H, Moallem DH, Seeram D, Dajiang S, Hibshoosh H, Jamison JK, Uhlemann AC, et al.

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

Pant S, Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, et al.

Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer

O'Connor CA, Harrold E, Lin D, Walch H, Gazzo A, Ranganathan M, Kane S, Keane F, et al.

Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication

Singh I, Chou JF, Capanu M, Park J, Yu KH, Varghese AM, Park W, Zervoudakis A, et al.

Multi-institutional comparison of ablative 5-fraction mr-guided online adapted vs. 15/25-fraction ct-guided offline adapted radiation therapy for locally advanced pancreas cancer

MD Chuong, E O’Reilly, R Herrera, M Zinovoy, KE Mittauer, M Rubens, ...

Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer

Bojmar L, Zambirinis CP, Hernandez JM, Chakraborty J, Shaashua L, Kim J, Johnson KE, Hanna S, et al.

NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3

Wainberg ZA, M O'Reilly E

NALIRIFOX Versus FOLFOX as First-oLine Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): Real-World Comparative Overall (OS) Survival Analysis

E O'Reilly, J Li, M DerSarkissian, R Chang, M Cheng, L Yu, D Rane, ...

NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem plus NabP) in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Subgroup analysis of …

T Macarulla Mercade, RA Pazo Cid, M Womack, A Cubillo Gracian, ...

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29 …

MA Hussein, G Khan, SR Chandana, RA Pazo Cid, I Kiss, J Gallego, ...

Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study

Randon G, Nakamura Y, Yaeger R, Lonardi S, Cremolini C, Elez E, Nichetti F, Ghelardi F, et al.

Next-generation therapies for pancreatic cancer

CW Buckley, EM O’Reilly

Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)

M Callahan, A Amin, FJ Kaye, MA Morse, MH Taylor, KJ Peltola, ...

Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.

W Park, J Zhang, F Dayyani, J Shan, R Liu, R Guo, EM O'Reilly, Z Liu, ...

Phase Ib/II, global, open-label, randomized evaluation of atezolizumab (atezo) plus etrumadenant (etruma) plus chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC

KP Kim, MP Sarvise, T Macarulla, A Alistar, E O'Reilly, M Boakye, ...

Phase Ib/II, global, open-label, randomized evaluation of atezolizumab (atezo)+ etrumadenant (etruma)+ chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC

K Kim, M Ponz-Sarvise, T Macarulla, A Alistar, EM O’Reilly, M Boakye, ...

Plant-based diet and survival among patients with metastatic colorectal cancer: Findings from CALGB/SWOG 80405 (Alliance)

E Cheng, FS Ou, C Ma, AP Venook, HJ Lenz, EM O’Reilly, PT Campbell, ...

Postoperative adverse events following neoadjuvant therapy and surgery for borderline resectable pancreatic cancer in a phase 2 clinical trial (alliance A021501)

RA Snyder, TJ Zemla, Q Shi, D Segovia, SA Ahmad, EM O’Reilly, ...

Postoperative complications following neoadjuvant therapy and surgery in a phase 2 borderline resectable pancreatic cancer clinical trial (Alliance A021501).

RA Snyder, TJ Zemla, Q Shi, DI Segovia, S Ahmad, EM O'Reilly, ...

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease

Keane F, Chou JF, Walch H, Schoenfeld J, Singhal A, Cowzer D, Harrold E, O'Connor CA, et al.

Quality of life (QOL) for patients with esophageal cancer receiving trimodality therapy with induction chemotherapy, chemoradiation, and surgery: Results from CALGB 80803 …

KA Goodman, AC Dueck, B Fruth, AM Noonan, A Shergill, TS Bekaii-Saab, ...

Radiation Quality Control in the PROSPECT Trial

HJ Mamon, Q Shi, KS Smith, B Colgrove, J Quigley, G Nelson, M Weiser, ...

Radiation therapy quality assurance analysis of alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable …

LT Tchelebi, D Segovia, K Smith, Q Shi, TJ Fitzgerald, MD Chuong, ...

Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery

Dee EC, Ng VC, O'Reilly EM, Wei AC, Lobaugh SM, Varghese AM, Zinovoy M, Romesser PB, et al.

Salvage hepatic artery infusion chemotherapy after first-line systemic failure in patients with unresectable cholangiocarcinoma.

N Nasar, M Armstrong, JF Chou, M Gonen, K Soares, VP Balachandran, ...

Second-line chemotherapy in localized pancreatic cancer: a systematic review and meta-analysis

EN Dekker, RR Narayan, MG Besselink, CH van Eijck, MY Homs, ...

Somatic mismatch repair deficiency in pancreas cancer (PC): Immune checkpoint blockade (ICB) outcomes and exploratory genomic analyses.

CA O'Connor, E Harrold, YT Lin, HS Walch, A Gazzo, SR Kane, F Keane, ...

Starting at the Front Line in Metastatic Pancreatic Cancers: As New Options Emerge, How Do You Select and Sequence?

ZA Wainberg, T Bekaii-Saab, E O'Reilly, S Pant

Survival after surgery for LAPC depends on post-induction CA19-9, CA19-9 decrease, performance status

E Dekker, D van Klaveren, Q Janssen, M Besselink, M Katz, E O’Reilly, ...

SWI/SNF Complex-Deficient Undifferentiated Carcinoma of the Pancreas: Clinicopathologic and Genomic Analysis

Yavas A, Ozcan K, Adsay NV, Balci S, Tarcan ZC, Hechtman JF, Luchini C, Scarpa A, et al.

T cell responses and clinical outcomes in pancreatic and colorectal cancer patients with minimal residual disease in AMPLIFY-201, a phase 1 trial of a first-in-class amphiphile …

ZA Wainberg, S Pant, CD Weekes, M Furqan, PM Kasi, CE Devoe, ...

Targeting KRAS in cancer

Singhal A, Li BT, O'Reilly EM

The comparative efficacy and safety of factor Xa inhibitors and warfarin for primary thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy

Chang YC, Song J, Chi KY, Gao W, Chang Y, Chiang CH, Hsia YP, Chiang CH

Therapeutic developments in pancreatic cancer

Hu ZI, O'Reilly EM

Tumor progression and tumor microenvironment of pancreas cancer ascites revealed by scRNA-seq and spatial transcriptomics

S Umeda, ER Karnoub, F Balogun, A Jiménez-Sánchez, ...

Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)

B Wolpin, DS Hong, A Spira, A Starodub, W Park, D Sommerhalder, ...

115 Comprehensive spatial, transcriptomic, and genomic analysis of immunogenic biliary tract cancer

W Park, F Keane, HS Ozkan, A Richards, V Rudneva, D Khalil, K Soares, ...

1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)

A Schram, T Macarulla, J Cleary, C Neuzillet, D Arnold, KA Reiss, ...

1619P Health-related quality of life with nalirifox versus nab-paclitaxel+ gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC …

D Melisi, T Macarulla, C de la Fouchardiere, RAP Cid, S Chandana, ...

1626P A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer

AM Varghese, T Golan, M Schattner, C Ang, M Gutierrez, M Passhak, ...

597P Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)

M Weiser, Q Shi, GJ Chang, L Hakki, J Goldberg, R Auer, M Gollub, ...

765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C …

EM O’Reilly, MH O’Hara, G Fisher, RA Wolff, ZA Wainberg, AH Ko, ...

A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX …

MH O'Hara, MM Wattenberg, I Garrido-Laguna, EM O'Reilly, MJ Yellin, ...

A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.

R Tuli, F Keane, JD Schoenfeld, C O'Connor, C White, JF Chou, ...

A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC).

F Keane, JD Schoenfeld, F Crowley, CA O'Connor, C White, C Schwartz, ...

A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance …

R Yaeger, Q Shi, AC Dueck, EG Dib, SMA Kazmi, OB Alese, ...

A single cell landscape of malignant pancreas cancer ascites

S Umeda, ER Karnoub, E Ziv, J Wu, C Cruz, W Park, F Balogun, ...

Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO).

F Keane, F Balogun, C O'Connor, F Crowley, A Chan, D Cowzer, JF Chou, ...

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, et al.

Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer

Raufi AG, May MS, Hadfield MJ, Seyhan AA, El-Deiry WS